Detalles de la búsqueda
1.
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Am J Respir Crit Care Med
; 209(3): 299-306, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37890129
2.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
N Engl J Med
; 385(9): 815-825, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34437784
3.
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
Am J Respir Crit Care Med
; 208(1): 59-67, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921081
4.
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Am J Respir Crit Care Med
; 208(1): 68-78, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154609
5.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Eur Respir J
; 62(6)2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37945033
6.
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
Am J Respir Crit Care Med
; 206(11): 1361-1369, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816621
7.
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Am J Respir Crit Care Med
; 203(12): 1522-1532, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33734030
8.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet
; 394(10212): 1940-1948, 2019 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31679946
9.
Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
FASEB J
; 30(6): 2435-50, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27006447
10.
Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion.
Am J Respir Cell Mol Biol
; 54(6): 831-42, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26600305
11.
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
Am J Respir Crit Care Med
; 190(8): 867-78, 2014 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25090037
12.
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
J Cyst Fibros
; 22(3): 464-470, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36581484
13.
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
J Cyst Fibros
; 22(4): 730-737, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36963986
14.
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Eur J Drug Metab Pharmacokinet
; 47(6): 817-825, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036885
15.
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
J Cyst Fibros
; 21(4): 675-683, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35190292
16.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Lancet Respir Med
; 10(3): 267-277, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34942085
17.
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
J Cyst Fibros
; 20(2): 234-242, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33339768
18.
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
J Cyst Fibros
; 20(1): 68-77, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32967799
19.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
J Cyst Fibros
; 20(2): 228-233, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586736
20.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Lancet Respir Med
; 9(7): 733-746, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581080